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Abstrakt -Zusammenfasung  
 
Von den durch Krebs verursachten Todesfällen weltweit entfallen die meisten auf 
Lungenkrebs. Trotz Fortschritten und Weiterentwicklungen in der Chirurgie, der 
Chemotherapie und der Radiotherapie über die letzten Jahrzehnte hinweg blieb die Todesrate 
von Lungenkrebs weitgehend unverändert, was hauptsächlich auf die Metastasenbildung der 
Krankheit und Mehrfachresistenzen zurückzuführen ist. Aufgrund der allgemein schlechten 
Prognose werden neue Behandlungsstrategien für Lungenkrebspatienten dringend benötigt. 
 
Das Ziel dieser Studie war es, Interaktionen zwischen Pemetrexed und Vinorelbin für 
menschliche Adenokarzinome mittels verschiedener Chemotherapieschemata zu untersuchen. 
Vinorelbin und Pemetrexed verursachten einen starken dosisabhängigen zytotoxischen Effekt 
sowohl bei HCC als auch bei HCC-res Zellen. Die IC50-Werte von Vin gegenüber HCC bzw. 
HCC-res Zellen betrugen 10.341.12 nM bzw. 9.982.12 nM. Die IC50-Werte von Pem 
gegenüber diesen Zellen betrugen 110.7717.28 nM bzw. 118.8918.77 nM. 
 
Die Anwendung verschiedener Therapieschemata induzierte eine signifikante, zeitabhängige 
Hemmung des Zellwachstums bei unbehandelten HCC und cisplatin-resistenten HCC Zellen. 
Das Therapieschema von Cisplatin→Pemetrexed→Vinorelbin zeigte den stärksten 
inhibitorischen Effekt sowohl bei HCC als auch bei HCC-res Zellen. 
 
Die Anwendung verschiedener Therapieschemata bei HCC und HCC-res Zellen erhöhte den 
Anteil von Apoptose betroffener Zellen, ausgenommen die alleinige Anwendung von 
Vinorelbin. Sowohl bei HCC als auch bei HCC-res Zellen stellte sich 
Cisplatin→Pemetrexed→Vinorelbin als effektivste Kombination zur Herbeiführung der 
Apoptose heraus. 
 
Die Anwendung verschiedener Therapieschemata bei HCC und HCC-res Zellen erhöhte die 
Konzentration von Calcium. Nur die alleinige Anwendung von Vin führte nicht zu einer 
Erhöhung der Calcium Konzentration in HCC Zellen. Der höchste Anstieg von der Calcium 
Konzentration wurde in den mit Cisplatin→Pemetrexed→Vinorelbin behandelten HCC sowie 
auch HCC-res Zellen nachgewiesen. 
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Wir zeigten, dass die sequenzielle Anwendung von Cisplatin, Vinorelbin und Pemetrexed 
einen synergetischen Effekt bei der Hemmung des Zellwachstums, der Herbeiführung von 
Apoptose sowie der  Erhöhung von der Calcium Konzentration gleichwohl in HCC und HCC-
res Zellen ausübt. Die Überfrachtung mit Calcium könnte zur Apoptose führen, was mit dem 
Inhibitionseffekt auf das Zellwachstum von Chemotherapeutika bei Lungenkrebszellen in 
Zusammenhang steht. Es liefert möglicherweise einen Beitrag zur Entwicklung 
chemotherapeutischer Ablaufpläne für Patienten und zur Überwindung von Cisplatin-
Resistenz bei Lungenkrebs. 
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Abstract - Summary 
 
Lung cancer is the leading cause of cancer deaths worldwide. Despite advances and 
progresses in surgery, chemotherapy, and radiotherapy over the last decades, the death rate 
from lung cancer has remained largely unchanged, which is mainly due to metastatic disease 
and multi drug resistance. Because of the overall poor prognosis, new treatment strategies for 
lung cancer patients are urgently needed. The aim of this study was to investigate the 
interactions between pemetrexed and vinorelbine for human adenocarcinoma via various 
chemotherapy schedules. 
 
Vinorelbine and pemetrexed caused a strong dose-dependent cytotoxic effect in both HCC 
and cisplatin resistant HCC (HCC-res) cells. The IC50 values of vinorelbine against HCC and 
HCC-res cells were 10.34±1.12 nM and 9.98±2.12 nM, respectively. The IC50 values of 
Pemetrexed against these cells were 110.77±17.28 nM and 118.89±18.77 nM respectively. 
The application of different therapy schedules induced a significant time dependent cell 
growth inhibition on HCC naïve and cisplatin resistant cells. The therapy scheme of 
cisplatin→pemetrexed→vinorelbine showed the strongest inhibitory effect on both HCC and 
HCC-res cells. 
 
The application of different therapy schedules on HCC and HCC-res cells increased the 
percentage of cells undergoing apoptosis, except the application of vinorelbine alone. In both 
HCC and HCC-res cells, cisplatin→pemetrexed→vinorelbine was found the most effective to 
induce apoptosis. 
 
The application of different therapy schedules on HCC and HCC-res cells increased 
cytoplasma calcium concentration. Only the application of vinorelbine alone failed to increase 
calcium concentration in HCC cells. The most elevated calcium concentration was found in 
the cells treated with cisplatin→pemetrexed→vinorelbine in both HCC and HCC-res cells 
As a conclusion, the sequential application of cisplatin, vinorelbine and pemetrexed has a 
synergistic effect in cell growth inhibition, apoptosis induction, and calcium concentration 
elevation in HCC and HCC-res cells. The calcium overload could lead to apoptosis, which 
was related to the cell growth inhibitory effect of chemotherapeutics in lung cancer cells. It 
might cast a light to develop chemotherapy schedules for patients, and to overcome cisplatin 
resistance in lung cancer. 
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1 INTRODUCTION 
 
1.1 Lung cancer and lung cancer therapy 
 
Lung cancer is the leading cause of cancer deaths worldwide. The two major forms of lung 
cancer are non–small cell lung cancer (NSCLC, about 85% of all lung cancers) and small-cell 
lung cancer (SCLC, about 15%) [1]. Lung cancer causes more deaths than the next three most 
common cancers combined (colon, breast and prostate), accounting for approximately 28% of 
all cancer deaths [2]. The lung cancer five-year survival rate (16.3%) is lower than many other 
leading cancer sites, such as the colon (65.2%), breast (90.0%) and prostate (99.9%), which 
accounts 52.6% for cases detected when the disease is still localized however only 15% of 
lung cancer cases are diagnosed at an early stage [3]. For distant tumors the five-year survival 
rate is only 3.5% and over half of people with lung cancer die within one year of being 
diagnosed [4]. 
Overall, women have an improved outcome compared with men across all ages and 
irrespective of histological subtype. A decrease in the age-adjusted lung cancer-related 
mortality in males has been observed since the 1990s. In females, the rate has reached a 
plateau after a long period of increase between the mid-1960s and 1995 [5]. Whether women 
are more vulnerable to tobacco carcinogens remains controversial. Women smokers are more 
likely than men to develop lung adenocarcinomas, and women who have never smoked are 
more likely to develop lung cancer than men who have never smoked. This difference has 
been attributed to estrogen signaling [6].  
The treatment and prevention of lung cancer are major unmet needs that can be improved by 
further investigation of more effective therapeutic plan with a better understanding of the 
molecular origins and evolution of the disease. 
Despite advances in early detection and standard treatment, NSCLC is often diagnosed at an 
advanced stage with a result in a poor prognosis [7]. Histologically NSCLC can be divided 
into three major subtypes: squamous-cell carcinoma, adenocarcinoma, and large-cell lung 
cancer. Smoking is related to all types of lung cancer but is most strongly linked with SCLC 
and squamous-cell carcinoma; adenocarcinoma is the most common type in patients with no 
smoking history [8]. Small cell lung carcinoma (SCLC) is an aggressive form of lung cancer 
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that is strongly associated with cigarette smoking and has a tendency for early dissemination 
[9]. 
Environmental factors, such as tobacco smoke, and genetic susceptibility interact to influence 
carcinogenesis, as well as other factors including genetic, hormonal, and viral factors. 
Occupational or environmental exposure to second-hand smoke, radon, asbestosis, and 
radiation represent other risk factors [10]. Tissue injury initially occurs in the form of genetic 
and epigenetic changes (e.g. mutations, loss of heterozygosity, and promoter methylation) and 
global transcriptome changes (e.g., inflammation and apoptosis pathways). These changes can 
persist long term and eventually lead to aberrant pathway activation and cellular function, 
such as dysregulated proliferation and apoptosis, to produce premalignant changes, including 
dysplasia and clonal patches. The changes can result in angiogenesis, invasion and early-stage 
cancer, and advanced cancer and metastasis [11].  
Progresses have been made for defining cancer risk, prognosis, and optimal therapy aimed at 
personalized prevention and treatment of lung cancer with the development of molecular 
techniques and biomarkers [12]. Lung cancer is initiated by activation of oncogenes or 
inactivation of tumor suppressor genes. Mutations in the K-ras proto-oncogene are present in 
10–30% of lung adenocarcinomas [13]. The epidermal growth factor receptor (EGFR) 
regulates cell proliferation, apoptosis, angiogenesis, and tumor invasion. Mutations and 
amplification of EGFR are common in NSCLC and provide the basis for treatment with 
EGFR-inhibitors [10]. A variant in the nicotinic acetylcholine receptor was found to be 
associated with nicotine dependence. Other candidates include 5p15.33, 15q25.1, and 6p21.33. 
Spitz et al. identified an association between an intronic SNP in the ACVR1B gene and 
cancer susceptibility in never smokers exposed to second-hand smoke by using a pathway-
based approach and focusing on single-nucleotide polymorphisms (SNP) in inflammatory-
pathway genes [14]. The p53 tumor suppressor gene, located on chromosome 17p, is affected 
in 60-75% of cases. Other genes that are often mutated or amplified are c-MET, NKX2-1, 
LKB1, PIK3CA, and BRAF [15]. There are multiple genetic and epigenetic changes in lung 
cancer, but in some types a specific driving genetic change is found like an activating EGFR 
mutation or and EML4-ALK overexpression. 
Risk models as well as other risk factors could eventually allow the identification of high-risk 
populations that might be good candidates for screening programs. Several randomized 
controlled studies have investigated the relationship between tobacco smoking as a major risk 
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factor and the impact of chest x-ray screening [16]. None of them has shown a reduction in 
lung cancer mortality, although it allows detection of early stage and asymptomatic lung 
cancers. Oken et. al. has recently reported that annual screening with chest X-ray was not 
found to be able to reduce lung cancer mortality as compared with usual care[17]. CT-scan, as 
significantly more sensitive tool than chest X-ray for identifying small and asymptomatic lung 
cancers, was evaluated in The National Lung Screening Trial (NLST). A low dose CT-scan in 
high risk individuals (current smokers with cigarette smoking history of more than 30 pack-
years, and former smokers who quit within the previous 15 years) was carried out. 
Participants who received low-dose CT scans had a 20% lower risk of dying from lung cancer 
than participants who received standard chest X-rays [18]. Several other studies are ongoing 
to validate the clinical benefit of this observation, but many questions remain to be solved in 
terms of frequency, duration, and cost-effectiveness of CT-scan before that evidence 
translates into policy and practice. Rapid progress and availability of whole genome 
sequencing, genome-wide analysis approaches may also uncover more targetable lesions in 
lung cancer, such as the K-Ras proto-oncogene [19]. 
Despite advances and progresses in surgery, chemotherapy, and radiotherapy over the last 
decades, the death rate from lung cancer has remained largely unchanged, which is mainly 
due to metastatic disease. Because of the overall poor prognosis, new treatment strategies for 
lung cancer patients are urgently needed. 
 
1.1.1 Non-small cell lung cancer 
 
NSCLC includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. 
NSCLC are frequently resistant to drug therapy and obtaining a complete response is rare. 
Therefore, the drug resistance in patients receiving chemotherapy alone or when combined 
with radiotherapy represents a major problem in cancer treatment of patients with NSCLC [7]. 
While there are several therapeutic options for the management of NSCLC, the disease is 
often not diagnosed until the advanced stage at which point therapy is not curative but to 
extend and improve quality of life (QOL) [20]. In 70% of the cases, patients are diagnosed 
with stage IV amenable only to systemic therapy. Combination chemotherapy is the current 
standard of care for patients with advanced NSCLC. NICE guideline recommended two-drug 
combination chemotherapy with a single third generation drug, such as pemetrexed, docetaxel, 
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gemcitabine, paclitaxel or vinorelbine, plus a platinum (carboplatin or cisplatin) for patients 
with preserved function status; single-agent therapy with a third generation drug should be 
given to the patients unable to tolerant a platinum-based combination [21]. Cisplatin is 
associated with slightly improved response rates, with no overall improvement of survival, 
and a different toxicity profile compared with carboplatin. In two meta analyses cisplatin was 
superior in overall survival in patients with non-squamous histology [22].As a major progress 
in recent years, Bevacizumab, a VEGF monoclonal antibody, has been approved in 
combination with carboplatin and paclitaxel in patients with non-squamous cell carcinoma 
and good performance status, negative for brain metastasis, and without hemoptysis or 
therapeutic anticoagulation [23]. In the FLEX study, cetuximab, an EGFR monoclonal 
antibody, has shown to improve survival in combination with cisplatin and vinorelbine in 
patients positive for EGFR expression identified via immunohistochemistry [10]. High EGFR 
expression has been recently reported as a predictive biomarker of survival benefit from the 
addition of cetuximab in K-Ras mutation in colon cancer [24].  
There is growing evidence indicating that accessory cells, also referred as stromal cells, play 
an essential role in disease progression in various cancers, including lung cancer. Regulated 
migration and homing of stem cells to tissue niches is a critical step during embryonic 
development or tissue repair, but also in cancer (stem-) cell dissemination [25]. A complex 
network of growth factors, cytokines, and chemokines is employed by the tumor cells in order 
to organize the microenvironment. Key players in tumor-microenvironment cross talk are 
mesenchymal stromal cells (MSC), monocyte/macrophage lineage cells, and T lymphocytes, 
along with extracellular matrix and blood vessels. Navab et al. demonstrated that carcinoma-
associated fibroblasts (CAFs) display a greater ability than normal fibroblasts to enhance the 
tumorigenicity in NSCLC [26]. 46 genes were identified overexpressed in CAFs via gene 
profiling, encoding for proteins that are involved in TGF-β signaling, focal adhesion, and the 
MAPK signaling pathway. Cells of monocytes/macrophage lineage are another highly 
important cell type in the tumor microenvironment. Tumor-associated macrophages (TAM) 
support lung cancer progression by inducing cancer cell motility and metastasis, and 
angiogenesis [27]. Among many factors released by TAM, CXCL12 is a prominent mediator 
accounting for TAM accumulation. An animal model recently highlighted the importance of 
peroxisome proliferator-activated receptor-γ (PPARγ) in TAM for promoting NSCLC 
progression and metastasis. Increased numbers of regulatory T cells (Treg) in the tumor 
microenvironment are thought to suppress immune recognition and immune response to the 
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neoplastic cells, thereby promoting tumor progression. NSCLC infiltration by Tregs was 
associated with earlier relapses, especially in patients with node-negative NSCLC [28]. 
 
1.1.2 Small cell lung cancer 
 
SCLC is an aggressive form of lung cancer that is strongly associated with cigarette smoking 
and has a tendency for early dissemination. Although most of the patients respond to 
chemotherapy, motility rate is still 95% of the patients [9]. SCLC accounts 14% of newly 
diagnosed lung cancer cases. The vast majority, more than 95%, of SCLC patients have 
smoking history [29].  
The specific sequence of genetic alteration of SCLC tumorigenesis remains unclear, however 
the genetic and molecular changes have been found to be related to SCLC: 1) Autocrine 
growth loops. Autocrine of gastrin-releasing peptide, neuromedin B, tyrosine kinase receptor 
c-kit have been found to be related to SCLC tumorigenesis. 2) Proto-oncogenes. The 
overexpression of MYC proteins in SCLC lead to more rapid proliferation and loss of 
terminal differentiation. 3) Tumor-suppressor genes. The loss of alleles from the short arm of 
chromosome 3 is the most common deletion of tumor DNA in SCLC, including genes as 
FHIT, RASSFIA, TP53, RB1 and PTEN [8].  
Patients with SCLC typically present with disseminated diseases. Symptoms include local 
ones such as cough, dyspnoea, chest pain, haemoptysis, and hoarseness, and distant ones such 
as weight loss, weakness, anorexia, paraneoplastic symptoms, and fever. SCLC tends to be 
centrally located with hilar masses and hilar and mediastinal adenopathy. Diagnosis is 
typically made by histological analysis of a bronchoscopic biopsy or percutaneous or 
transbronchial aspiration samples [29].  
Combination chemotherapy remains the major treatment for SCLC. The administration of 
four to six cycles etoposide and cisplatin plus chest radiotherapy for patients with good 
performance status and limited stage disease produces a complete-response rate of 80% or 
even higher, median survival excess of 17 months, and 5-year tumor-free of 12-25% [30]. 
Combination chemotherapy remains the focus of treatment for patients with extensive-stage 
diseases, which leads to a complete-response rate of about 20% and median survival of about 
7 months. Changes in combination of chemotherapy medications and schedule of 
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chemotherapy cycle have been investigated. Some trials have shown slight survival benefits 
favoring the regimens with three or four drugs but at the cost of greater toxicity.  The use of 
weekly chemotherapy resulted in greater toxicity with no survival advantage. And neither 
shortened interval between cycles nor maintenance therapy was found to provide consistent 
benefit for the patients treated [9].  
Most patients with small-cell lung cancer relapse within a year of starting treatment. The 
likelihood of response to subsequent therapy can be predicted on the basis of the response to 
previous therapy and the duration of drug-free interval. Patients who did not respond to 
previous therapy or who relapsed within 3 months of completing therapy are judged refractory, 
whereas those who had responded to previous treatment and relapsed 3 months or longer after 
completing such treatment are deemed sensitive. 
 
1.2 Multi-drug resistance  
 
Multidrug resistance (MDR) is defined as a protection of the cells against numerous drugs, 
with different chemical structures and by different intracellular functional mechanisms, like 
Anthracyclines (doxorubicin, daunorubicin, et al.), Epipodophyllotoxins (etoposide, 
teniposide, et al.), Vinca alkaloids (vincristine, vinblastine, et al.), Taxanes (paclitaxel, 
docetaxel, et al.), Kinase inhibitors (imatinib, flavopyridol, et al.) and other preparation 
classes. MDR turns into an extraordinary limitation to cancer chemotherapy. There are 
different mechanisms involved in MDR, including:  
Abnormal expression of membrane protein drug pumps. The ABC transporters ABCB1, 
ABCC1, ABCC2, ABCC3, ABCC4, ABCC5 and ABCG2 have been discovered to be 
implicated in MDR. So far ABCB1 (also known as Pgp) has been found to transport the 
largest number of drugs. The same drug can be a substrate of different ABC transporters 
while ABC transporters have distinct substrate specificities [31, 32].  
Abnormality of intracellular enzyme systems. DNA topoisomerase (Top) is a ribozyme for 
DNA replication and transcription. Down-regulation of Top expression and change in the type 
of expression are important reasons for SCLC resistance to Top inhibitors.  
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Abnormality of cell apoptosis. Apoptosis escape in tumor cells starts from the activation of 
anti-apoptotic pathways via extracellular signals; insensitization of the endogenous cell death 
machinery via resisting apoptotic protein “addiction”; and loss of apoptosis-promoting tumor 
suppressor genes via accumulated mutations. Integrinsplay an important role in inducing cell 
apoptosis and blocking metastasis. In cell adhesion mediated drug resistance, extracelluar 
matrix (ECM) protein can resist apoptotic signals induced by cytotoxic drugs. In more than 
80% SCLC cases, a loss of p53 activity has been found.  
Enhancement of cell repair systems. Studies in recent years show that DNA mismatch repair 
(MMR) plays a very important role in the progression of SCLC chemoresistance. Down-
regulation of MMR gene MLH1 and MSH2 may be associated with the occurrence and MDR 
of lung cancer. There may be a link to silencing of MMR genes induced by acetylation and 
phosphorylation of histones and hypermethylation of promoters. 
The resistance of tumour cells to chemotherapy agents can be caused by a number of cellular 
adaptations, including reduced uptake, inactivation by glutathione and other anti-oxidants, and 
increased levels of DNA repair or DNA tolerance. Chemotherapy agents, including cisplatin, 
pemetrexed, and vinorelbine, are transported in tumour cells via ABC transporters, the over 
activation and/or over expression can result in chemotherapy resistance. Treatment with these 
agents is characterized by resistance, both acquired and intrinsic. For instance, the 
overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of 
platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin [33]. 
Pemetrexed gains cell entry via several of ABC transporters, and other mechanisms. The 
resistance to pemetrexed can occur in a number of circumstances, such as catalytic activity or 
expression of FPGS alteration, membrane transport alternation, reducing the availability of 
free antifolate substrate to react with FPGS, increased cellular levels of natural folates, and 
increased activity of γ-glutamyl hydrolase [20]. Vinorelbine is transported via efflux pump 
ABCC10&MRP7 and RLIP76, a non-ABC transporter, to conferring drug accumulation 
defect and resistance in lung cancer cells. Bessho et. al. found the gene expression of 
ABCB1/MRP1 and ABCC10/MRP7 in vinorelbine resistant NSCLC cell lines [34].  
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1.3 New therapeutic strategy  
 
There is a rich drug development pipeline of novel chemotherapeutic agents for lung cancer 
such as amrubicin, SABA, picoplatin, belotecan and vinflunine. Amrubicin is a synthetic 
anthracycline that blocks DNA repair by inhibiting Top I [35-37]. Clinical trials have shown 
that the response rate of combined use of amrubicin and picoplatin is as high as 88%, and the 
median survival is 13.6 months [7]. Picoplatin is a platinum analogue that overcomes 
platinum drug resistance, with lower ototoxicity and nephrotoxicity  than those of other 
platinum drugs [38]. 
Some molecular targeted drugs have entered clinical trials, including matrix metalloproteinase 
(MMP) inhibitors, thalidomide, biological vaccines, and small molecular weight inhibitors 
directed at receptor protein tyrosine kinases such as EGFR, c-Kit and VEGFR [39]. 
Unfortunately, the therapeutic effects are unsatisfactory. MMPs regulate extracellular matrix 
modelling, maintaining cell growth and morphology. Up-regulation of MMP is considered a 
marker for poor prognosis of SCLC [36]. However, some large-scale randomized phase III 
clinical trials suggest that use of MMP inhibitor marimastat and tanomastat as maintenance 
therapy after failing induction therapy did not seem to prolong the survival of NSCLC 
patients [40]. C-Kit protein has been found highly expressed in lung cancer, to stimulate cell 
growth signalling pathways in an autocrine or paracrine manner [41]. Imatinib can inhibit 
activities of c-Kit receptor tyrosine kinase, bcr/ abl fusion protein and platelet-derived growth 
factor receptor (PDGFR) family tyrosine kinase [42]. KIT gene can encode transmembrane 
tyrosine kinase growth factor receptor of the PDGFR family. However, phase II clinical trials 
have shown that imatinib did not prolong progression-free survival (PFS) of sensitivity and 
drug resistance-induced relapse of SCLC patients with high expression of c-Kit [43]. And no 
additional therapeutic effect was observed after treatment on the basis of the platinum plus 
irinotecan schedule. Thalidomide is a multi-target angiogenesis inhibitor, that inhibits 
vascular endothelial growth factor (VEGF), fibroblast growth factor β (FGFβ) and tumor 
necrosis factor α (TNFα), and modify intracellular matrix [44]. Phase III clinical trials using 
thalidomide on the basis of carboplatin+etoposide and using thalidomide for maintenance 
therapy showed satisfactory tolerance and response [45]. Pravastatin also exhibited its 
inhibitory effect on SCLC growth and sensitizing effect on chemotherapeutic agents. Targeted 
mitochondrial apoptosis pathway is an SCLC drug resistance-reversing strategy.  It was found 
in a phase I clinical trial that the Bcl-2 targeted inhibitor Oblimersen relieved 86% of 
untreated ES-SCLC cases [46]. It was found in a pre-clinical study that drug resistance to 
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ABT- 263 in a SCLC cell line and a transplanted tumor model was accompanied with the 
increased concentration of apoptosis-promoting protein Bax, Bim and NOXA [6]. A 
combined use of spindle toxic drugs and apoptosis-targeted inhibitors may produce a 
synergistic pro-apoptotic effect through double inhibition of anti-apoptotic protein Mcl-1 and 
Bcl-xl [47]. It has been demonstrated in SCLC cell line in vitro and NSCLC transplanted 
tumor models that combined use of Bcl-xl targeted inhibitor Navitoclax (ABT-263) and 
spindle toxic drugs could induce apoptosis of tumors cells in mitotic arrest phase [48]. 
 
1.4 Pemetrexed  
 
Pemetrexed (Alimata®) is a multi-targeted antifolate cytotoxic agent approved in Europe and 
US as first line therapy in combination with cisplatin, and as monotherapy after prior 
chemotherapy, or as maintenance monotherapy, for patients with local advanced or metastatic 
non-squamous or predominant non-squamous NSCLC [49]. It is applied in combination with 
cisplatin in patients with malignant pleural mesothelioma, bladder, breast, cervical, colorectal, 
gastric, head and neck, and pancreatic cancers.  
Pemetrexed is a pyrrolo [2, 3-d] pyrimidine-based antifolate and has antineoplastic effects by 
disturbing folate-dependent metabolic processes essential for cellular replication. Pemetrexed 
inhibits thymidylate synthase (TS) and at a lower efficacy for other secondary enzyme targets, 
including glycinamide ribonucleotide formyltransferase, aminoimidazolecarboxamide 
ribonucleotide formyltransferase (AICARFT), and rapamycin pathway, which is responsible 
for the balance of cellular energy metabolism, protein and lipid synthesis and growth) [27]. 
Thymidylate synthase plays an important role in DNA biosynthesis by catalysing the 
methylation of fluorodeoxyuridine monophosphate (dUMP) to deoxythymidine 
monophosphate (dTMP). High TS expression levels correlate with key mechanisms of 
antimetabolite drug resistance. TS expression levels predicted survival in untreated NSCLC 
patients and postoperative recurrence of pulmonary adenocarcinomas. An association of TS 
expression with response to S-1 plus carboplatin in advanced NSCLC was also reported 
recently [50]. 
Pemetrexed gains cellular entry via the reduced folate transporter, the α-folate receptor, and 
proton-coupled folate transporter. Intracellular pemetrexed is polyglutamated to its active 
form by folylpolyglutamate synthetase (FPGS), which results in accumulation of pemetrexed 
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derivatives with greater affinity for its enzyme targets mentioned above than the parent drug 
[20]. Induction of apoptosis, modulation of EGFR and Akt phosphorylation, and alternations 
in the expression of critical tumorigenesis genes involved in the activity of pemetrexed are 
mechanistic contributors to the synergistic interaction.  
Pemetrexed has a steady-state volume of distribution of approximately 16 L. It is 
approximately 81% bound to plasma proteins in vitro. It undergoes minimal hepatic 
metabolism. The total systemic clearance is around 92 ml/min and the plasma elimination 
half-life is 3.5 h in patients with normal renal function. The drug is predominantly eliminated 
unchanged in the urine, with between 70% and 90% of a dose recovered unchanged within 24 
h of administration [51].  
The efficacy of pemetrexed in patients with NSCLC has been demonstrated in several clinical 
trials, in combination with cisplatin as first-line therapy, monotherapy as second-line therapy, 
and as maintenance monotherapy. Pemetrexed plus cisplatin was non-inferior to gemcitabine 
plus cisplatin with median overall survival was 10.3 months with both treatments [52]. But 
pemetrexed did appear to have survival advantages in patients with non-squamous diseases. In 
patients whose disease had not progressed with four cycles of first-line platinum-based 
therapy, median progression-free survival and overall survival times in patients who received 
pemetrexed plus best supportive care were significantly longer than placebo control group. It 
has been suggested in different studies that the treatment paradigm may provide QOL 
advantage for the patients. Most trials that investigated the duration of first-line platinum-
based therapies have received equivalent survival between the shorter and longer therapy 
durations. Immediate maintenance therapy after four cycles of platinum-based therapy is a 
promising approach [50].  
Pemetrexed is generally well tolerated and the tolerability profile is favourable as 
combination therapy with cisplatin and also as monotherapy in patients with advanced 
NSCLC. Adverse events have been reported as neutropenia, skin rash, nausea or vomiting, 
mucositis and diarrhoea. 
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1.5 Vinorelbine 
 
Vinorelbine (Navelbine®) is a semisynthetic vinca alkaloid derivative that demonstrates 
strong antitumor activity in various malignancies. It is indicated as a single agent or in 
combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, 
advanced NSCLC [39]. It is also applied in patients with breast cancer, SCLC, ovarian 
carcinoma, cervical carcinoma, B-cell malignancies, Hodgkin’s disease, and multiple 
myeloma. 
It exerts a cytotoxic effect upon rapidly proliferating tumors through prevention of mitotic 
spindle formation by inhibiting the polymerization of tubulin into microtubules. The vinca 
alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and 
catharanthine, with the catharanthine unit being the site of structural modification for 
vinorelbine [53]. The antitumor activity of vinorelbine is thought to be due primarily to 
inhibition of mitosis at metaphase through its interaction with tubulin. It may also interfere 
with amino acid, cyclic AMP, and glutathione metabolism, calmodulin-dependent calcium 
transport ATPase activity, cellular respiration, and nucleic acid and lipid biosynthesis [54]. 
The pharmacokinetic properties of intravenously administered vinorelbine are: after a dose of 
30 mg m–2 i.v. a high initial peak of 5 µmol rapidly decays to about 1 nmol at 2 h. 
Distribution in blood is rapid, with binding of 78% of the drug to platelets and a further 13.5% 
to plasma proteins with only 1.7% left as free drug in the first 2 h after administration. 
Subsequently, binding to plasma proteins is in the order of 70–80% [55]. The drug diffuses 
freely into tissues showing a large volume of distribution and an elimination half-life of 40 h. 
30 minutes after administration, high levels of vinorelbine are found in both normal lung and 
tumour tissue and diffusion out of tumour tissue appears to be slow. The metabolism of 
vinorelbine is principally hepatic and only 11% of the drug is excreted via the renal route, the 
majority being eliminated through faecal excretion [56].  
Vinorelbine is widely utilized in combination chemotherapy for NSCLC. In different clinical 
studies, the cisplatin vinorelbine combination showed a superior response-rate of 30% 
compared to 19% for cisplatin-vindesine and 14% for vinorelbine alone; 1-year survival rates 
were 35%, 27% and 30% respectively. Combined chemotherapy and radiotherapy is a 
common approach in the treatment of NSCLC. Cisplatin-vinorelbine was used as the 
induction regimen in patients with stage III-B disease prior to radical radiotherapy with an 
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objective response of 48%, leading the authors to conclude that this is an effective regimen 
pre-radiotherapy [57].  
 
1.6 Calcium signalling 
 
1.6.1 Calcium channels and pumps 
 
The calcium ion is a ubiquitous cellular signal, which regulates various cellular processes by 
activating or inhibiting cellular signalling pathways and calcium-regulated proteins, such as 
gene transcription, muscle contraction, synaptic transmission, cell proliferation and apoptosis 
[58]. Cells have to shape calcium signals in the dimensions of time, space, and amplitude in 
order to carry out the calcium controlled cell biology activities.  
Calcium channels, pumps and exchangers control the complex and tight regulation of calcium 
homeostasis, which differ in their cellular distribution and their mechanism of transport. A 
strict equilibrium between the ‘on’ and ‘off’ mechanisms in the cells keeps calcium under 
regulation within cellular compartments to achieve the sensitive control of cell signalling 
pathways that can precisely respond to many stimuli. Resting cytoplasm free Ca2+ ([Ca2+]c) is 
maintained at a low level (100nM), with a much higher extracellular Ca2+ concentration of 
1.2 mM [59]. The calcium ‘on’ mechanisms include the plasma membrane (PM) channels, 
which regulate the calcium supply from extracellular space, the endoplasmic reticulum (ER) 
and sarcoplasmic reticulum (SR) channels [60]. An equally set of ‘off’ to remove calcium 
from the cytoplasm includes calcium ATPases on the PM and ER/SR, and additionally to 
exchangers that utilize gradients of ions to provide the energy to transport calcium out of the 
cell, such as Na+/Ca2+ exchange. Mitochondria also play an important role in the regulation of 
cytoplasm calcium. These calcium stores have a low affinity but high-capacity rapid calcium 
uniporter that can significantly reduce cytoplasmic calcium transients and diminish cellular 
responses.  
Within the cell there is a calcium concentration gradient between the cytoplasm and the Ca2+ 
stores. The calcium stores are enriched with calcium binding proteins, such as calsequestrin 
and calreticulin. Ca2+ can be released from the stores by the generation of inositol 1, 4, 5-
trisphosphate (IP3) [61]. IP3 is highly mobile in the cytoplasm and diffuses into the cell 
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interior where it encounters specific IP3 receptors (IP3Rs) on ER/SR. The binding of IP3 
changes the conformation of IP3Rs so that an integral channel is opened, thus allowing the 
Ca2+ in the ER/SR to enter the cytoplasm. IP3Rs are composed of four subunits (1200 kDa), 
encoded by three different genes [46]. The opening of IP3Rs is enhanced by the modest 
increase of Ca2+ concentration (0.5-1 M) whereas higher Ca2+ concentration ( 1 M) 
inhibits the opening. Ryanodine receptors (RyRs) are structurally and functionally analogous 
to IP3Rs, with an approximately twice the conductance and molecular mass of IP3R [62]. 
RyRs are generally actived by the increase of Ca2+ of 1-10 M and inhibited by higher Ca2+ 
concentration of  10 M. They are largely present in excitable cell types [63]. The opening 
of these channels has been shown to be modulated by numerous factors, including 
phosphorylation, adenine nucleotides, thiol reactive compounds, pH level and the Ca2+ load of 
ER/SR [60]. Other than the Ca2+ channels on ER/SR, there are also Ca2+ ATPase pumps 
which actively transport Ca2+ against a concentration gradient, such as the 
sarcoplasmic/endoplasmic reticulum Ca2+ ATPases (SERCAs) pumping Ca2+ into the ER.  
There are mainly three types of calcium entry channels: (1) receptor-operated calcium 
channels (ROCCs), which comprise a range of structurally and functionally diverse channels. 
They are particularly prevalent on secretory cells and at nerve terminals. ROCCs are activated 
by the binding of an agonist to the extracellular domain of the channel [64]. (2) voltage-
operated calcium channels (VOCCs), which are largely employed by excitable cell types such 
as muscle and neuronal cells, where they are activated by depolarisation of the PM. (3) store-
operated calcium channels (SOCCs), which are activated in response to depletion of the 
intracellular calcium stores, either by physiological calcium -mobilising messengers or 
pharmacological agents. SOCCs are the most ubiquitous PM calcium channels. The 
mechanisms of how the SOCCs sense the status of the intracellular pool are unknown. 
 
1.6.2 Calcium and cancer 
 
Since calcium signalling can affect pathways regulating proliferation and apoptosis, 
alterations in calcium channels and pumps could have a causal and promoting role in cancer. 
The location, degree and temporal aspects of changes in cytoplasm calcium concentration 
regulate the pathways relating to tumorigenesis.  
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Alternations in calcium channels and pumps are detected in many cancers. SOCCs as IP3R2 
and IP3R3 were found over expressed in non-small cell lung cancer and gastric cancer 
respectively [24, 65]. Down-regulation of SERCA 2 was discovered in oral cancer [66], colon 
cancer [67], thyroid cancer [68] and lung cancer [67] but up-regulation in colorectal cancer 
[69]. SERCA 3 was found down regulated in colon cancer [70]. Changes in the expression or 
activity of PMCA pumps and transient receptor potential channels, such as TRPM8, TRPM1, 
TRPV1, TRP6, and TRPC6, were also found in several types of cancers [61].      
Calcium is implicated in cellular motility including neurite outgrowth and contraction [58, 71]. 
Calcium, is also a key regulator of signalling pathway important in angiogenesis, since some 
angiogenic stimuli, such as vascular endothelial growth factor, can increase cytoplasm 
calcium concentration by mobilizing calcium  release from the internal calcium stores [72].  
Calcium  can influence genomic stability and cell survival, for example calcium  is a 
modulator of poly (ADP-ribose) polymerase-1 (PARP1) activity, which alters cellular 
metabolism and DNA repair [73]. Calcium  is a key regulator of the cell cycle, and hence 
proliferation, through various different pathways including Ras signalling [74]. Calcium 
signalling is implicated in the cancer cell differentiation process either through the 
extracellular calcium-sensing receptor and/or through changes in intracellular calcium  [75]. 
Calcium can modulate cell-cycle regulators directly, for example by activating the 
transcription of the genes crucial in the G0-G1 transition [76] and for the phosphorylation of 
retinoblastoma protein in late G1 phase [77]. Calcium can also indirectly regulate the 
subcellular localization of the key tumorigenic proteins. Minaguchi et al. found out that the 
nuclear localization of PTEN is regulated by Calcium through a tyrosil phosphorylation-
independent conformational modification in major vault protein [76]. The accumulation of 
excessive calcium  has often been found to link to apoptosis and necrosis by the activation of 
ER/SR and mitochondrial membrane permeabilization [78]. A reduction of ER calcium  
content is associated with resistance to apoptosis [46].  
    
1.6.3 Target calcium in cancer   
 
Calcium channels and pumps with altered expression and/or activity in cancer might represent 
potential biomarkers of disease. Changes in the ER calcium  pump SERCA3 protein 
expression is either reduced or lost in colon carcinomas compared with normal tissue, 
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consistent with a loss of differentiation in cancer cells [79]. The increased apoptotic resistance 
of the malignant neuroendocrine differentiated prostate cells is due to a general alteration in 
calcium homeostasis in which the reduction in SERCA2b has an important role. The reduced 
ER calcium content partially because of the decrease of SERCA2b expression is a probable 
mechanism for apoptotic resistance [80]. These calcium channels and pumps can be used as 
prognostic indicators or can guide treatment by the means of techniques such as microarrays 
in cancers. 
Calcium channels and pumps with altered expression offer the potential not only as biomarker 
for cancer diagnosis but also anticancer therapeutic targets. So modulating the activity of 
calcium channels and pumps that are aberrantly expressed in cancer cells and cancer stem 
cells efficiently might sufficiently interrupt calcium homeostasis to target cancer cells with 
restricted tissue distribution.  
The significance of increased expression of calcium channels and pumps in cancer is directly 
related to the calcium regulated tumorigenic pathways. Many of the calcium channels and 
pumps with altered expression in cancer have a highly restricted tissue distribution, unlike 
many of the ubiquitous potential anticancer drug targets such as cell cycle regulator. 
Therapies based on a target with a limited tissue distribution are less associated with 
generalized toxicity, which is a factor limiting clinical use for agents that have widespread 
expression. For instance, PMCA2 is up-regulated in human breast cancer cell lines, whereas 
its expression is restricted normally to the central nervous system [81].  
The availability of pharmacological calcium channels and pumps inhibitors or activators 
makes it as an outstanding feature of calcium channels or pumps as cancer targets. For 
instance heparin, dantrolene and CPA are inhibitors for IP3R, RyR and SERCA, while 
adenophostin A and suramin are activators for IP3R and RyR (SERCA activator has not been 
discovered) [82-84].  
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2 METHODS AND MATERIALS  
 
2.1 Biological material  
 
Tumor cell lines 
HCC-78: DSMZ no. ACC 563, human non-small cell lung carcinoma. According to the 
histological classification of the original tumor, HCC is defined as adenocarcinoma (Virmani 
et. al., 1998) and characterized as cytokeratin +, cytokeratin-7 +, cytokeratin-8 +, cytokeratin-
17 +, cytokeratin-18 +, cytokeratin-19 +, desmin -, endothel -, EpCAM +, GFAP -, 
neurofilament -, vimentin +.  
HCC-78 cisplatin resistant cell line: generated from HCC-78 cell line via cisplatin treatment 
selection, and maintained with low dose cisplatin in culture. It has been developed by 
continuously exposing cells to gradually increasing doses of cisplatin and use of the limiting 
dilution technique [85].  
 
2.2 Lab material and equipment 
 
2.2.1 Laboratory consumables 
 
 Multi-well dishes: 96-well and 6-well, Cat. 353072, 353935 and 351146, Falcon, BD 
Biosciences Labware, NJ, US. 
 Cell culture dishes: 35 × 10 mm and 100 × 20 mm, Cat. 353001 and 353003, Falcon, 
BD Biosciences Labware, NJ, US. 
 Centrifuge tubes: 15 ml and 50 ml, Cat. 62 554 502 and 227 261, Sarstedt AG & Co., 
Nümbrecht, Germany. 
 Cryotubes: Cryo Vials, Cat. 121 277, Greiner Bio-One GmbH, Frickenhausen, 
Germany.   
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 Filter system: 500 ml, 0.22 µm filter, Cat. 430758, Corning Incorporated, NY, US  
 Slides: 25 × 1.0 × 75 mm, superfrost, Cat. J1800AMNZ, Menzel-Gläser, Mezel GmbH 
& Co KG, Braunschweig, Germany. 
 Cover slides: 24 × 32 mm and 18 × 18 mm, Menzel-Gläser, Mezel GmbH & Co KG, 
Braunschweig, Germany.   
 Counting chamber: 0.1 × 0.0025 mm2, Cat. 63510-10, Neubauer, Brand, Germany.  
 Pipettes: 10 ml, Cat. 47110, Sterilin Ltd. Caerphilly, UK; 25 ml, Cat. 4251, Corning 
Incorporated, US. 
 Tips: 10 µl, 200 µl, 1000 µl, Cat. 70 1115, 70 760 002 and 70 762, Sarstedt AG & Co., 
Nümbrecht, Germany. 
 Culture flasks: 25 cm2, 2 µm vent cap, Cat. 430639, Corning Incorporated, NY, US; 
75 cm2 and 175 cm2, 2 µm vent cap, Cat. 658175 and 660175, Greiner Bio-One 
GmbH, Frickenhausen, Germany.   
 
2.2.2 Lab equipment 
 
 Thermomixer: 5436, Eppendorf-Netheler-Hinz GmbH, Hamburg, Germany. 
 Magnetic stirrer: IkaMag RH, Janke & Kunkel IKA-Labortechnik, Staufen, Germany.  
 Centrifuge: Hettich EBA 12R and Universal 16A, Minnesota, US.   
 Eppendorf pipettes: 0.5-10 µl, 10-100 µl, 20-200 µl, 100-1000 µl, Eppendorf-
Netheler-Hinz GmbH, Hamburg, Germany. 
 Electronic pipette controller: Gilson, Middleton, US.   
 Water bath: Techne TE-10D, Tempunit Gesellschaft für Laborgeräte mbH, Wertheim, 
Germany. 
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2.3 Cell culture 
 
2.3.1 Cell culture medium and supplement 
 
 RPMI 1640: Cat. F1415, Biochrom AG, Berlin, Germany. 
 Trypsin-EDTA: 0.05%/0.02% in D-PBS, Cat. L11-004, PAA Laboratories GmbH, 
Pasching, Austria. 
 Fungizone: amphothericin B, 250 µg/ml, Cat. P11-001, PAA Laboratories GmbH, 
Pasching, Austria. 
 Penstrep: penicillin (10,000 IU/ml) and streptomycin (10,000 IU/ml), Cat. P11-010, 
PAA Laboratories GmbH, Pasching, Austria. 
 L-glutamine: 200 mM, Cat. M11-004, PAA Laboratories GmbH, Pasching, Austria. 
 FBS: REF. 16170-078, Gibco, Darmstadt, Germany. 
 PBS: Phosphate Buffered Saline, without Ca2+ and Mg2+, Cat. H15-002, PAA 
Laboratories GmbH, Pasching, Austria. 
 Ethanol: pure, Pharmacy, Klinikum Grosshadern, Munich, Germany.  
 DMSO:  dimethyl sulfoxide, 5 ×10 ml. Cat. D2650, Sigma-Aldrich, St. Louis, US.  
 Trypan blue: 0.4%, Cat. T8154, Sigma-Aldrich, St. Louis, US.  
 Cisplatin: 1 mg, Pharmacy, Klinikum Grosshadern, Munich, Germany.  
 Pemetrexed: 1 mg, Pharmacy, Klinikum Grosshadern, Munich, Germany.  
 Vinorelbine: 1 mg, Pharmacy, Klinikum Grosshadern, Munich, Germany.  
 
2.3.2 Cell culture equipment 
 
 Laminar airflow: Heraeus, Munich, Germany. 
 Incubator: Heraeus, Munich, Germany. 
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2.3.3 Cell culture medium recipe 
 
 HCC medium 
Final Conc. 
90%                  RPMI 1640 
10%                  FBS heat inactivated 
200 mM            L-glutamine 
10,000 IU/ml    Penstrep 
2.5 µg/ml          Fungizone 
 
2.3.4 Monolayer culture of lung cancer cell line HCC 
 
HCC cells were cultured in 175 cm2 culture flasks with 25 ml medium and cultured in the 37 
°C cell incubator with 5% CO2. Every 2-3 days the culture medium was changed and they 
were split with Trypsin-EDTA solution and incubated in the cell incubator for 5 min when the 
cells were 60-70% confluent. The cells were frozen in liquid nitrogen with 10% DMSO 
culture medium for future use.  
 
2.3.5 Survival curve 
 
HCC cells (1×105) were seeded in 25 cm2 cell culture flask and cultured for 24 h, and 
afterward treated with pemerexed and vinorelbine. For cisplatin treatment, the chemotherapy 
drug was added 3 h before pemetrexed or vinorelbine. The cell viability was evaluated after 
the cells were exposed to the treatment for 24 h, 48 h, 72 h and 96 h by trypan blue exclusion 
cell counting. This approach was chosen because after application of cisplatin to human, a 
relevant plasma concentration of unbound cisplatin (active form) persists for only 3 h [60]. 
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2.4 Apoptosis measurement via flow cytometry  
2.4.1 Material and equipment 
 
 FACSAria II flow cytometer: BD, New Jersey, USA.  
 Alexa Fluor: 350 annexin V conjugate, Cat. A23202, Invitrogen, Darmstadt, Germany. 
 Propidium iodide: 1 mg/ml, Cat. P4170, Sigma-Aldrich, St. Louis, US.     
 
2.4.2 FACS analys 
 
Single-cell suspensions of HCC cells, 1 × 106/ml in 2% FBS RPMI 1640, were treated with 
cisplatin, pemetrexed and vinorelbine according to the schedule for 48 h. The cells were 
harvested after the incubation period and wash in cold PBS. Re-centrifuge the washed cells, 
discard the supernatants, and then resuspend the cells in annexin-binding buffer. Determine 
the cell density and dilute in annexin-binding buffer to ca. 1 × 106 cells/mL, preparing a 
sufficient volume to have 100 μl per assay. Add 5 μl of the annexin V conjugate to each 100 
μl of cell suspension. Incubate the cells at room temperature for 15 minutes. Propidium iodide 
was added with a final concentration of 5 μg/106 cells to discriminate viable and non-viable 
cells before measurements. Cells were analyzed with FACSAria II flow cytometer as soon as 
possible. The population separated into at least two groups: live cells with only a low level of 
fluorescence and apoptotic cells with substantially higher fluorescence intensity. 
  
2.5 Calcium staining 
 
2.5.1 Calcium staining material 
 
 Fura-2 calcium imaging calibration kit: 11 Ca2+ standard buffers premixed with 50µM 
fura-2, Cat. F-6774, Molecular Probes, Invitrogen, Eugene, US. 
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 Fura-2 AM: 50 µg × 20 special packaging, Cat. F14185, Molecular Probes, Invitrogen, 
Eugene, US. 
 
2.5.2 Composition of fluorescent microscope for calcium imaging  
 
 Microscope: Axiovert 200M, SIP 79800, Carl Zeiss AG, Jena, Germany. 
 HBO lamp: 103W/2, short Arc mercury lamp, Osram GmbH, Augsburg, Germany. 
 Objective Fluar: 20 × 0.75, transmission wavelength from 340 nm, Zeiss AG, 
Oberkochen, Germany. 
 Filters: excitation wavelength 340 nm and 380 nm, emission wavelength 510 nm both, 
Cat. 340 AF 15 and 380 AF 15, Laser components GmbH, Olching, Germany. 
 CCD digital camera: AxioCam MRm, Carl Zeiss Vision, Munich, Germany. 
 
2.5.3 Fura-2 calibration curve 
 
A ratio metric measurement method was utilized to determine the dissociation constant (Kd) 
of Fura-2 AM at the staining condition, in order to reduce artifacts from the microscope 
application and to generate the absolute cytoplasm calcium concentration [86].  
With the Fura-2 calcium imaging calibration kit, images of different calcium concentration 
standard solution with Fura-2 AM were acquired, with excitation at 340 nm and 380 nm 
respectively, while the emission was measured at 510 nm, according the protocol offered with 
the kit. With the online Kd calculator (www.probes.com), the Kd of Fura-2 AM was yielded 
as 269 nM [87]. (Figure 1) 
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Figure 1. Fura-2 calcium calibration curve: the Kd of Fura-2 AM was yielded as 269 nM. 
  
A ratio (R) of emission intensities was calculated as the emission intensity at 510 nm from 
340 nm excitation divided by the emission intensity at 510 nm from 380 nm excitation (R = 
F340/F380). According the equation below, the cytoplasm free calcium concentration can be 
obtained from the fluorescence emission intensity ratio: 
 
 
 
2.5.4 Cytoplasm calcium concentration measurement  
 
HCC cells were seeded in cell culture dishes with the same density. After the cells grew 
adherent, Fura-2 AM was applied with a final concentration of 10 µM in 37°C cell incubator 
[Ca2+]free = 
R-Rmin 
Rmax-R 
× × Kd 
F380max 
F380min 
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for 90 min. After loading, the cells were incubated another 30 min in PBS (with Ca2+ and 
Mg2+) to allow complete dye deesterification and they were examined with the fluorescent 
microscope.  
Images of the same field were taken at both exciting wavelength 340 nm and 380 nm with the 
image-processing program Axio Vision 4.1 (Carl Zeiss). For each image, ROIs were defined 
in cytoplasm of every single cell, and the average fluorescence of ROIs was measured with 
the image-processing program Scion Image 4.0 (Scion). Cytoplasm calcium concentration 
was calculated as described above.  
 
2.6 Statistics  
 
One-way or two-way ANOVA (combined with pairwise multiple comparisons) were 
performed using Sigma Stat software (Jandel Scientific, Chicago, USA). A p-value of less 
than 0.05 was considered statistically significant. 
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3 RESULTS 
 
3.1 Inhibitory effect of vinorelbine and pemetrexed on cell growth 
 
Adeno lung carcinoma cells HCC and cisplatin resistant cells HCC-res were treated with 
vinorelbine and pemetrexed in a dose range of 0.1 nM up to 10 µM and 1 nM up to 100 µM 
respectively. Both HCC and HCC-res cells showed sensitivity to vinorelbine and pemetrexed. 
Vinorelbine and pemetrexed caused a strong dose-dependent cytotoxic effect in both HCC 
and HCC-res cells.  
In HCC cells, survival was inhibited down to 7.57% after 24 h exposure to vinorelbine at the 
highest concentration, while HCC-res cells to 9.98%. In HCC cells, survival was inhibited 
down to 30.30% after 24 h exposure to pemetrexed at the highest concentration, while HCC-
res cells to 35.42%.  
The IC50 values of vinorelbine against HCC and HCC-res cells were 10.34±1.12 nM and 
9.98±2.12 nM, respectively. The IC50 values of pemetrexed against these cells were 
110.77±17.28 nM and 118.89±18.77 nM respectively. (Figure 2) 
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Figure 2. Inhibitory effect of vinorelbine and pemetrexed on cell growth: HCC and HCC-
res cells were treated with different concentrations of vinorelbine and pemetrexed for 24 h. 
Error bars are not shown for clarity. Both HCC and HCC-res cells showed sensitivity to 
vinorelbine and pemetrexed. Vinorelbine and pemetrexed caused a strong dose-dependent 
cytotoxic effect in both HCC and HCC-res cells.  (n=3)  
 
3.2 Effect of vinorelbine, pemetrexed and different chemotherapy schedule on cell 
growth 
 
HCC cells were treated with different schedule of combination of 1 µM cisplatin, 12 nM  
vinorelbine, and 130 nM pemetrexed respectively and the survival fraction was calculated 
every 24 h for 4 days after treatments. The schedules included single drug treatments (Cis, 
Vin, Pem), double drug combined treatments (Cis→Vin, Cis→Pem, Vin+Pem, Vin→Pem, 
and Pem→Vin), and triple drug combined treatments (Cis→Vin+Pem, Cis→Vin→Pem, 
Cis→Pem→Vin). The survival rate in all treatment groups were calculated with non-
treatment control group.  
In all treated groups, a significant time dependent cell growth inhibition could be shown. In 
HCC cells, the cell number decreased after 24 h treatment, the lowest survival fraction was 
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observed in the group treated with Cis→Pem→Vin at 96 h after the treatment as 
1.17%±0.35%. (n = 3) (Figure 3A)  
 
 
 
 
Figure 3A. Effect of vinorelbine, pemetrexed and different chemotherapy schedule on 
cell growth (all groups) in HCC cells: The schedules included single drug treatments (Cis, 
Vin, Pem), double drug combined treatments (Cis→Vin, Cis→Pem, Vin+Pem, Vin→Pem, 
and Pem→Vin), and triple drug combined treatments (Cis →Vin+Pem, Cis →Vin→Pem, 
Cis→Pem→Vin) for 4 days. In all treated groups, a significant time dependent cell growth 
inhibition could be shown. Error bars are not shown for clarity.  (n=3, * = P<0.05 versus other 
experimental groups) 
 
An additional inhibition effect was shown when the survival fraction in the combination of 
vinorelbine, pemetrexed and cisplatin treated groups were compared with that of cisplatin 
administrated alone.  
The combination of Cis→Vin and Cis→Pem resulted in 12.67±2.51% and 7.28±2.02% 
survival fraction at 96 h after treatment respectively, comparing with exposure alone 
(31.20±6.92% of Vin, 21.57±3.61% of Pem and 26.23±6.22% of Cis).  
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Meanwhile when HCC cells treated with a triple drug schedule, the schedule of 
Cis→Pem→Vin exhibited the strongest inhibitory effect at 96 h after treatment with a 
survival fraction of 1.17%±0.35%. In the groups of Cis→Vin+Pem, and Cis→Vin→Pem, the 
survival fraction at 96 h after treatment were 3.38±1.23% and 3.99±1.07% respectively. (n = 3) 
(Figure 3B)  
 
 
 
 
Figure 3B. Effect of vinorelbine, pemetrexed and different chemotherapy schedule on 
cell growth (groups include cisplatin in the schedule) in HCC cells: HCC cells treated with 
Cis, Cis→Vin, Cis→Pem, Cis→Vin+Pem, Cis→Vin→Pem, Cis→Pem→Vin for 4 days. An 
additional inhibition effect was shown when the survival fraction in the combination of 
vinorelbine, pemetrexed and cisplatin treated groups were compared with that of cisplatin 
administrated alone. Error bars are not shown for clarity.  (n=3, * = P<0.05 versus other 
experimental groups) 
 
Cisplatin resistant HCC cells HCC-res were treated with different schedule of combination of 
cisplatin, vinorelbine, and pemetrexed respectively and the survival fraction was calculated 
every 24 h for 4 days after treatments. The schedules were applied the same as those of HCC 
cells. The survival rate in all treatment groups were calculated with non-treatment control 
group. Cis did not show cell growth inhibitory effect in HCC-res cells.  
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In all other treated groups, a significant time dependent cell growth inhibition could be shown, 
and the cell number decreased after 24 h treatment with the lowest survival fraction observed 
in the group treated with Cis→Pem→Vin at 96 h after the treatment as 2.30%±0.37%. (n = 3) 
(Figure 4A)  
 
 
 
 
 
Figure 4A. Effect of vinorelbine, pemetrexed and different chemotherapy schedule on 
cell growth (all groups) in HCC-res cells: HCC-res cells treated with included single drug 
treatments (Cis, Vin, Pem), double drug combined treatments (Cis→Vin, Cis→Pem, 
Vin+Pem, Vin→Pem, and Pem→Vin), and triple drug combined treatments (Cis→Vin+Pem, 
Cis→Vin→Pem, Cis→Pem→Vin) for 4 days. In the treated groups except Cis treated group, 
a significant time dependent cell growth inhibition could be shown. Error bars are not shown 
for clarity.  (n=3, * = P<0.05 versus other experimental groups) 
 
A significant stronger inhibition effect was shown when the survival fraction in the 
combination of vinorelbine, pemetrexed and cisplatin treated groups were compared with that 
of cisplatin administrated alone or the control group.  
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The combination of Cis→Vin, Cis→Pem resulted in 10.27±2.82% and 14.43±2.62% survival 
fraction at 96 h after treatment respectively, comparing with exposure alone (26.97±7.91% of 
Vin, 15.11±2.68% of Pem and 90.54±3.29% of Cis).  
Meanwhile when HCC cells treated with a triple drug schedule, the schedule of 
Cis→Pem→Vin exhibited the strongest inhibitory effect at 96 h after treatment with a 
survival fraction of 2.30%±0.65%. In the groups of Cis→Vin+Pem, and Cis→Vin→Pem, the 
survival fractions at 96 h after treatment were 4.28±0.33% and 5.48±0.87% respectively. (n = 
3) (Figure 4B)  
 
 
 
 
Figure 4B. Effect of vinorelbine, pemetrexed and different chemotherapy schedule on 
cell growth (groups include cisplatin in the schedule) in HCC-res cells: HCC-res cells 
treated with Cis, Cis→Vin, Cis→Pem, Cis→Vin+Pem, Cis→Vin→Pem, Cis→Pem→Vin for 
4 days. An inhibition effect was shown when the survival fraction in the combination of Vin, 
Pem and Cis treated groups were compared with that of Cis administrated alone. Error bars 
are not shown for clarity.  (n=3, * = P<0.05 versus other experimental groups) 
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3.3 Effect of vinorelbine, pemetrexed and different chemotherapy schedule on 
apoptosis  
 
In order to investigate the effect of 12 nM vinorelbine, 130 nM pemetrexed and combined 
schemes on programmed cell death in HCC cells, different therapy schedule has been applied 
on HCC and HCC-res cells with or without cisplatin treatment. Apoptosis was measured after 
48 h.  
In HCC cells, the percentages of apoptotic cells in all treated groups except vinorelbine 
treated group were significantly higher than that of the control group. Single drug exposure of 
cisplatin, vinorelbine, and pemetrexed resulted in 34.48±7.04%, 20.94±8.75% and 
46.00%±8.62% cell apoptosis respectively.  
Sequential double drug application of Cis→Vin, or Cis→Pem resulted in 32.48±3.65% and 
39.01±3.20% cell apoptosis respectively. Simultaneous exposure of Vin+Pem resulted in 
41.85±3.44% cell apoptosis while sequential application of Vin→Pem or Pem→Vin as 
47.45±5.52% and 54.91±5.97%.  
Most interestingly, in the schemes of triple drug treatments, the highest apoptosis percentage 
was found in Cis→Pem→Vin as 50.28±13.18%, which was comparable to Pem→Vin. (n = 3) 
(Figure 5)  
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Fiure 5. Effect of vinorelbine, pemetrexed and different chemotherapy schedule on 
apoptosis in HCC cells: apoptosis was analysed after the cells were treated with different 
schedule of combination of cisplatin, vinorelbine, and pemetrexed respectively for 24 h. The 
percentages of apoptotic cells in all treated groups except vinorelbine group were significantly 
higher than the control group. (n=3, * = P<0.05 versus other experimental groups) 
 
In HCC-res cells, apoptosis was analysed after the cells were treated with different schedule 
of combination of 1 µM cisplatin, 12 nM vinorelbine, and 130 nM pemetrexed respectively 
for 24 h. Cisplatin treatment showed no effect on apoptosis in HCC-res cells. The percentages 
of apoptotic cells in all other treated groups except vinorelbine were significantly higher than 
that of the control group. Single drug exposure of vinorelbine and pemetrexed resulted in 
23.37±3.07%, and 42.94%±6.85% cell apoptosis respectively.   
Sequential double drug application of Cis→Vin or Cis→Pem resulted in 28.39±5.38% and 
44.00±5.29% cell apoptosis respectively. Simultaneous exposure of Vin+Pem resulted in 
43.65±6.07% cell apoptosis while sequential application of Vin→Pem or Pem→Vin as 
40.31±2.79% and 37.17±10.92%.  
In the schemes of triple drug treatments, the highest apoptosis percentage was found in 
Cis→Pem→Vin as 51.88±9.74%. (n = 3) (Figure 6)  
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Figure 6. Effect of vinorelbine, pemetrexed and different chemotherapy schedule on 
apoptosis in HCC-res cells: apoptosis was analysed after the cells were treated with different 
schedule of combination of cisplatin, vinorelbine, and pemetrexed respectively for 24 h. The 
percentages of apoptotic cells in all treated groups except vinorelbine group were significantly 
higher than the control group. (n=3, * = P<0.05 versus other experimental groups) 
 
3.4 Effect of vinorelbine, pemetrexed and different chemotherapy schedule on 
cytoplasma Ca2+ 
 
Different therapy schedule has been applied on HCC and HCC-res cells with or without 
cisplatin treatment. Cytoplasm free calcium concentration was measured after 48 h.  
In HCC cells, cytoplasm free calcium concentration in all treated groups except vinorelbine 
treated group was significantly elevated than that of the control group. Single drug exposure 
of vinorelbine and pemetrexed resulted in cytoplasm free calcium concentration of 
176.52±86.23 nM and 265.28±67.39 nM respectively.   
Sequential double drug application of Cis→Vin or Cis→Pem resulted in cytoplasm free 
calcium concentration of 256.25±57.86 nM and 377.11±112.81 nM respectively. 
Simultaneous exposure of Vin+Pem resulted in cytoplasm free calcium concentration of 
261.58±68.45 nM while sequential application of Vin→Pem or Pem→Vin as 368.42±92.20 
nM and 277.06±48.39 nM respectively.  
In the schemes of triple drug treatments, the highest cytoplasm free calcium concentration 
was found in Cis→Pem→Vin treated group as 694.05±170.15 nM. (n=3) (Figure 7) 
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Figure 7. Effect of vinorelbine, pemetrexed and different chemotherapy schedule on 
cytoplasm free calcium in HCC cells: Different therapy schedule has been applied on HCC 
cells with or without cisplatin treatment. Cytoplasm free calcium concentration was measured 
after 48 h. Cytoplasm free calcium concentration in all treated groups except vinorelbine 
group was significantly elevated than that of the control group. (n=3, * = P<0.05 versus 
control group) 
 
In the cisplatin resistant HCC-res cells, 1 µM cispatin failed to induce a cytoplasm free 
calcium concentration increase. In HCC-res cells, cytoplasm free calcium concentration in all 
other treated groups except vinorelbine treated group was significantly elevated than that of 
the control group.  
Single drug exposure of vinorelbine and pemetrexed resulted in cytoplasm free calcium 
concentration of 149.48±38.88 nM and 304.77±78.48 nM respectively.   
Sequential double drug application of Cis→Vin or Cis→Pem resulted in cytoplasm free 
calcium concentration of 152.14±42.04 nM and 357.64±42.83 nM respectively. Simultaneous 
exposure of Vin+Pem resulted in cytoplasm free calcium concentration of 274.56±86.14 nM 
while sequential application Vin→Pem or Pem→Vin as 359.85±73.65 nM and 266.32±58.36 
nM respectively.  
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In the schemes of triple drug treatments, the highest cytoplasm free calcium concentration 
was found in Cis→Pem→Vin as 391.19±76.58 nM, which was significantly lower than that 
of treated HCC cells. (n=3) (Figure 8) 
 
 
 
 
Figure 8. Effect of vinorelbine, pemetrexed and different chemotherapy schedule on 
cytoplasm calcium in HCC-res cells: Different therapy schedule has been applied on HCC-
res cells with or without cisplatin treatment. Cytoplasm free calcium concentration was 
measured after 48 h. Cytoplasm free calcium concentration in all treated groups except 
cisplatin and vinorelbine treated groups was significantly elevated than that of the control 
group. (n=3, * = P<0.05 versus control group) 
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4 DISCUSSION 
 
4.1 Schedule-dependent cytotoxic synergism in lung cancer cell lines 
 
Mehta et. al. examined chemotherapeutic combination in breast cancer and found that the 
median time to disease progression and survival was significantly shorter for patients treated 
with any combination of agents, exhibiting either extreme or intermediate in vitro drug 
resistance, in comparison with patients having tumours with low in vitro resistance to both 
drugs [88]. In order to investigate the different effect of therapeutic schedules in adeno lung 
cancer cells, different schemes with vinorelbine and pemetrexed with or without cisplatin 
were applied on adeno lung carcinoma HCC and cisplatin resistant adeno lung carcinoma 
HCC-res cells. 
HCC and HCC-res cells have shown sensitivity to both pemetrexed and vinorelbine. 
Pemetrexed has shown cytotoxic activity in several human cell lines, including lung 
carcinoma cell lines, which agrees with its cell growth inhibitory effect on HCC cell line.  
Animal studies have shown that vinorelbine has favourable antitumor activity on lung cancer 
cells and can induce cellular differentiation. Recently, much interest has been focused on the 
therapeutic efficacy of vinorelbine in NSCLC. Clinical studies demonstrated that vinorelbine 
has antitumor activity in patients with advanced NSCLC as a single agent and in combination 
with other anticancer agents including cisplatin or gemcitabine. Moreover, vinorelbine has 
been proven to improve the patient’s QOL as well as prolong survival of elderly NSCLC 
patients with poor performance status [89].  
The therapeutic scheme as sequential application of pemetrexed and vinorelbine with or 
without cisplatin has shown a synergistic effect in cell growth inhibition, while simultaneous 
exposure of pemetrexed and vinorelbine and converse application sequence, with or without 
cisplatin, did not provide antagonistic or additive effect in cell growth in both HCC and HCC-
res cells. Pemetrexed has been found to induce synchronization of cell cycle events. For 
instance, it was shown in CCRF-CEM lymphocytic leukemia cells that apoptosis was 
preceded by accumulation at the G1/S interface within 12 h of pemetrexed application, after 
which the cell population entered S phase synchronously. Cellular accumulation in the S 
phase may sensitize cells to the cytotoxic effects of other chemotherapeutic drugs. In colon 
carcinoma cell line, the cytotoxicity of gemcitabine was increased significantly with 
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pemetrexed added 24 h previously [20]. Additional synergistic cytotoxicity has been 
demonstrated with pemetrexed in combination with other chemotherapeutics agents in 
NSCLC in vitro and in vivo, including cisplatin, carboplatin, and oxaliplatin. The effect of 
radiotherapy was also found to be enhanced with pemetrexed pre-application. Administration 
of pemetrexed prior to fractionated radiation therapy delayed tumor growth in mice with 
NSCLC xenografts. Schedule dependent cytotoxic effect in NSCLC cell lines has been shown 
with pemetrexed in combination with erlotinib. Synergism was most pronounced with 
exposure to pemetrexed plus erlotinib for 24 h followed by erlotinib for 48 h [90].  
Dan Zhang et al. has investigated in pemetrexed-resistant cell lines, and shown that the cells 
maintained sensitivity to 5-fluorouracil, docetaxel, SN-38, and vinorelbin; however, all of the 
cell lines showed cross-resistance to cisplatin [91].  
  
4.2 Effect of pemetrexed, vinorelbine and combined chemotherapy schedules on the  
calcium homeostasis and apoptosis in lung cancer cell lines  
 
Squamous cell lung carcinomas origin from metaplastic bronchial epithelium and small cell 
lung carcinomas are believed to origin from neuro-epithelial bodies. But the origin of large 
cell carcinomas and adeno carcinomas is less clear [86]. It has been known for a long time 
that calcium signals govern a host of vital cell functions and so are necessary for cell survival. 
More recently, it has become more clear that cellular calcium overload or perturbation of 
intracellular calcium compartmentalization can cause cytotoxicity and trigger apoptosis or 
necrotic cell death [92]. Ca2+-dependent processes are involved with the caspases, the 
mainstream apoptosis executioners, and the interfering with the sequestration of calcium into 
intracellular pools as ER can be sufficient to trigger apoptosis as part of a stress response [93]. 
The earliest link that was found between calcium and apoptosis was that calcium induced a 
typical apoptosis ladder-like DNA fragmentation pattern in isolated thymocytes nuclei 
through the activation of a Ca2+ -and Mg2+ -dependent endonuclease [94]. It has been 
discovered in mouse T-lymphocytes that high-dose pharmacologically raising cytoplasmic 
calcium resulted in apoptosis but low-dose treatment gave a resistant capacity to apoptosis 
[95]. It has been demonstrated that increased cytoplasm free calcium concentration is 
involved in number of cellular event, including apoptotic pathways. The elevation of 
cytoplasm calcium concentration might be the result of calcium entering from extracellular 
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space or calcium being released from intracellular calcium stores. In apoptosis, it results in an 
increase in the mitochondrial calcium concentration, which opens the permeability transition 
pore followed by an efflux of cytochrome C. As a consequence, cytochrome C amplifies the 
calcium release from the ER and activates the intrinsic apoptotic pathway via caspase 9 [96].  
The sequential application of pemetrexed and vinorelbine with or without cisplatin has shown 
a synergistic effect to increase cytoplasm calcium concentration and apoptosis, which 
confirmed the relationship between increase of cytoplasm calcium and apoptosis by cytotoxic 
agents. Recent advances in elucidating the molecular biology of lung carcinogenesis have 
elucidated novel drug targets, and treatments are rapidly evolving into specialized agents that 
hone in on specific aspects of the disease. Of particular interest is blocking tumor growth by 
targeting the physiological processes surrounding angiogenesis, pro-tumorigenic growth 
factor activation, anti-apoptotic cascades and other cancer-promoting signal transduction 
events. The effect of the chemotherapy compounds and combination of these on calcium and 
apoptosis would light up a new perspective in cancer therapy and mechanism of 
tumorigenesis. 
 
4.3 Outlook 
 
Worldwide, lung cancer is the most common cancer in terms of both incidence and mortality 
with the highest rates in Europe and North America. First-line chemotherapy often leads to 
encouraging responses in lung cancer, but during the treatment process, resistance to the 
chemotherapy frequently occurs and ultimately limits the life expectancy of the patient. The 
combination of novel chemotherapeutic schedules might be a solution other than new drug 
development.  
Therefore, the incorporation of new combination of vinorelbin, pemetrexed with cisplatin into 
the therapeutic regimens of adenocarcinoma of the lung casts light into the cancer therapy 
field. A new therapy strategy could be to combine the chemotherapy medication with 
consideration of different cytotoxic mechanisms, in order to destruct tumour. Clinical trials 
could verify these findings. 
As the therapeutic combination of vinorelbin, pemetrexed and cisplatin has not been 
investigated in adeno carcinoma, although it has been utilized in NSCLC treatment and 
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showed promising effect. My findings support the further clinical usage of the chemotherapy 
schemes in lung cancer therapy. The combination with targeted therapy, anti-oncogenic 
molecules as Hedgehog inhibitors, anti-RAS, AKT, or MEK molecules could be also 
beneficial to tumors with more than oncogenic mechanisms involved. A new class of 
therapeutic agents as combination partner could be investigated in the future. 
Moreover, the further research into cytotoxic mechanism in lung cancer and interaction 
between different chemotherapeutics still needs to be done, for instance the molecular 
changes and the cross talk between oncogenic pathways. Since it has been found in our work 
that vinorelbin, pemetrexed, and combination of different schedules influences the 
homeostasis of calcium and apoptosis, as the universe second messenger, the effect of 
cytotoxic agents on calcium signalling was shown. To understand and utilize distinct 
comprehension of calcium signalling and chemotherapy is necessary for the furthermore set 
up of new cancer therapy methods.  
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5 CONCLUSION 
 
In this study, vinorelbine and pemetrexed caused a strong dose-dependent cytotoxic effect in 
both HCC cells (adenocarcinoma of the lung) and HCC-res cells (resistant against cisplatin). 
The IC50 values of vinorelbine against HCC and HCC-res cells were 10.34±1.12 nM and 
9.98±2.12 nM, respectively. The IC50 values of pemetrexed against these cells were 
110.77±17.28 nM and 118.89±18.77 nM respectively. 
The application of different therapy schedule including pemetrexed and vinorelbine with or 
without cisplatin treatment induced a significant time dependent cell growth inhibition on 
HCC naïve and cisplatin resistant cells. The therapy scheme of sequential application of 
Cis→Pem→Vin showed the strongest inhibitory effect on both HCC and HCC-res cells. 
The application of different therapy schedules including pemetrexed and vinorelbine with or 
without cisplatin treatment on HCC naïve and cisplatin resistant cells increased the percentage 
of cells undergoing apoptosis, except application of vinorelbine alone. In both HCC and 
HCC-res cells, sequential application of Cis→Pem→Vin was found the most effective to 
induce apoptosis. 
The application of different therapy schedules including pemetrexed and vinorelbine with or 
without cisplatin treatment on HCC naïve and cisplatin resistant cells increased cytoplasm 
calcium concentration except application of vinorelbine alone failed to increase cytoplasm 
calcium concentration in HCC cells. The most elevated cytoplasm calcium concentration was 
found in the cells treated with sequential application of Cis→Pem→Vin in both HCC and 
HCC-res cells. The calcium overload could lead to apoptosis, which was related to the cell 
growth inhibitory effect of chemotherapeutics in lung cancer cells.  
Sequential application of cisplatin, pemetrexed and vinorelbine has shown a synergistic effect 
in cell growth inhibition, apoptosis induction, and cytoplasm calcium concentration elevation 
in adeno lung carcinoma cells and also cisplatin resistant adeno lung carcinoma cells.  
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APPENDIX I – LIST OF FIGURES 
 
 
Figure 1. Fura-2 calcium calibration curve 
Figure 2. Inhibitory effect of vinorelbine and pemetrexed on cell growth 
Figure 3A. Effect of vinorelbine, pemetrexed and different chemotherapy schedule on cell 
growth (all groups) in HCC cells 
Figure 3B. Effect of vinorelbine, pemetrexed and different chemotherapy schedule on cell 
growth (groups include cisplatin in the schedule) in HCC cells 
Figure 4A. Effect of vinorelbine, pemetrexed and different chemotherapy schedule on cell 
growth (all groups) in HCC-res cells 
Figure 4B. Effect of vinorelbine, pemetrexed and different chemotherapy schedule on cell 
growth (groups include cisplatin in the schedule) in HCC-res cells 
Fiure 5. Effect of vinorelbine, pemetrexed and different chemotherapy schedule on apoptosis 
in HCC cells 
Figure 6. Effect of vinorelbine, pemetrexed and different chemotherapy schedule on apoptosis 
in HCC-res cells 
Figure 7. Effect of vinorelbine, pemetrexed and different chemotherapy schedule on 
cytoplasma Ca2+ in HCC cells 
Figure 8. Effect of vinorelbine, pemetrexed and different chemotherapy schedule on 
cytoplasma Ca2+ in HCC-res cells 
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APPENDIX II - LIST OF ABBREVIATIONS 
 
NSCLC: non-small cell lung cancer 
SCLC: small cell lung cancer 
Cis: cisplatin 
Pem: pemetrexed 
Vin: vinorelbine 
EGFR: epidermal growth factor receptor 
SNP: single-nucleotide polymorphisms 
NLST: National Lung Screening Trial 
QOL: quality of life 
MSC: mesenchymal stromal cells 
CAFs: carcinoma-associated fibroblasts  
TAM: Tumor-associated macrophages 
PPARγ: peroxisome proliferator-activated receptor-γ 
Treg: regulatory T cells 
ABC transporter: ATP-binding cassette transporter 
MDR: multidrug resistance 
Top: topoisomerase 
ECM: extracelluar matrix  
MMR: mismatch repair  
MMP: matrix metalloproteinase  
PDGFR: platelet-derived growth factor receptor 
DISC: death inducing signal complex 
PFS: progression-free survival  
VEGF: vascular endothelial growth factor  
FGFβ: fibroblast growth factor β  
TNFα: tumor necrosis factor α  
TS: thymidylate synthase  
AICARFT: aminoimidazolecarboxamide ribonucleotide formyltransferase  
dUMP: fluorodeoxyuridine monophosphate  
dTMP: deoxythymidine monophosphate 
FPGS: folylpolyglutamate synthetase 
ER: endoplasmic reticulum 
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SR: sarcoplasmic reticulum 
[Ca2+]c: cytoplasm free Ca2+ 
[Ca2+]ER: endoplasmic reticulum Ca2+ 
SOCC: store-operated Ca2+ channel 
VOCC: voltage-operated Ca2+ channel 
ROCC: receptor-operated Ca2+ channel 
IP3: inositol 1, 4, 5-trisphosphate 
IP3R: inositol 1, 4, 5-trisphosphate receptor 
RyR: ryanodine receptor 
SERCA: sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 
PARP1: poly ADP-ribose polymerase-1 
ROI: regions of interest 
CPA: cyclopiazonic acid 
Kd: dissociation constant 
HCC-res: HCC cisplatin resistant cell 
ROI: region of interest 
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